Surgical Science (Q3 Review): More to prove - Redeye

Surgical Science (Q3 Review): More to prove - Redeye

SUS reported Q3 sales and EBIT below our expectations. License revenue grew by 16%, and US sales within Educational Products remained strong. The quarter lacked the growth seen in Q2, and the miss opened the trapdoor for the share, falling c10%.

Länk till analysen i sin helhet: https://www.redeye.se/research/1193015/surgical-science-q3-review-more-to-prove?utm_source=finwire&utm_medium=RSS